Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright

Ikena Oncology, Inc. (NASDAQ:IKNA) – Equities researchers at HC Wainwright raised their FY2024 EPS estimates for shares of Ikena Oncology in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.95) per share for the year, up from their previous estimate of ($1.07). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Ikena Oncology’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($0.70) EPS.

Ikena Oncology (NASDAQ:IKNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08.

Separately, Wedbush reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a research report on Thursday, November 7th.

Ikena Oncology Trading Down 1.1 %

Shares of NASDAQ:IKNA opened at $1.74 on Thursday. The company has a market capitalization of $83.97 million, a PE ratio of -1.41 and a beta of 0.48. Ikena Oncology has a 12-month low of $1.22 and a 12-month high of $2.32. The business’s fifty day simple moving average is $1.71 and its 200-day simple moving average is $1.65.

Institutional Trading of Ikena Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Owl Capital Holdings LP increased its holdings in shares of Ikena Oncology by 5.1% during the second quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock valued at $6,750,000 after acquiring an additional 200,000 shares in the last quarter. BML Capital Management LLC increased its stake in Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock valued at $1,251,000 after purchasing an additional 138,174 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Ikena Oncology by 813.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after buying an additional 457,245 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in shares of Ikena Oncology by 230.7% during the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after buying an additional 266,904 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of Ikena Oncology by 15.2% during the second quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock valued at $536,000 after buying an additional 42,931 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.